Results 101 to 110 of about 105,114 (279)

SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT trial

, 2015
Purpose: nab-Paclitaxel plus gemcitabine was superior to gemcitabine alone for patients with metastatic pancreatic cancer (MPC) in the phase III MPACT trial.
Lopez Casas, P.P., Illei, P., Von Hoff, D.D., Romano, A., Musteanu, Mónica Andrea, López-Ríos Moreno, Fernando, Plaza Hernández, José Carlos, Pierce, D., Tabernero, J., Menendez, C., Wei, X., Hidalgo, M., Heise, C., Brachmann, C.B.   +13 more
core   +1 more source

Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
In the murine triple‐negative breast cancer (TNBC) model, chemotherapy effectively increases tumor neoantigen burden (TNB). Here, the study constructs a liposomal nanovaccine using antigens derived from in vitro chemotherapy‐treated paclitaxel‐resistant TNBC 4T1 cells.
Bo Chen, Yangyi Wang, Tingting Li, Changqing Guo, Zhe Xie, Zhixian Zhang, Xinghua Han, Wei Wang, Jian Wang, Xiaopeng Ma, Yuanzeng Min   +10 more
wiley   +1 more source

cNEK6 induces gemcitabine resistance by promoting glycolysis in pancreatic ductal adenocarcinoma via the SNRPA/PPA2c/mTORC1 axis

Cell Death and Disease
Resistance to gemcitabine in pancreatic ductal adenocarcinoma (PDAC) leads to ineffective chemotherapy and, consequently, delayed treatment, thereby contributing to poor prognosis. Glycolysis is an important intrinsic reason for gemcitabine resistance as
Ge Li, Fei-Fei She, Cheng-Yu Liao, Zu-Wei Wang, Yi-Ting Wang, Yong-Din Wu, Xiao-Xiao Huang, Cheng-Ke Xie, Hong-Yi Lin, Shun-Cang Zhu, Yin-Hao Chen, Zhen-heng Wu, Jiang-Zhi Chen, Shi Chen, Yan-Ling Chen   +14 more
doaj   +1 more source

Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine

Molecules, 2017
One of the main obstacles for cancer therapies is to deliver medicines effectively to target sites. Since stroma cells are developed around tumors, chemotherapeutic agents have to go through stroma cells in order to reach tumors.
Yasuhiro Tsume, Adam J. Drelich, David E. Smith, Gordon L. Amidon   +3 more
doaj   +1 more source

Designing Tissue Function Through Embedded Bioprinting Architectures

Advanced Science, EarlyView.
Embedded bioprinting enables soft, cell‐dense constructs to be fabricated within supporting bath environments. This review introduces a function‐guided framework linking target tissue functions to architectural requirements, supporting bath selection, bioink design, printing dynamics, and validation assays.
Qi Li, Yifei Cao, Jiaxin Lin, Huayong Yang, Hongzhao Zhou   +4 more
wiley   +1 more source

Ultrasonic locating devices for central venous cannulation: meta-analysis [PDF]

, 2003
OBJECTIVES: To assess the evidence for the clinical effectiveness of ultrasound guided central venous cannulation. DATA SOURCES: 15 electronic bibliographic databases, covering biomedical, science, social science, health economics, and grey ...
Beverley, C., McWilliams, Richard, Davidson, Andrew, Beverley, Catherine, Paisley, S., Thomas, S., Davidson, A., Paisley, Suzy, Calvert, Neill, Hind, Daniel, Hind, D., Thomas, Steven, Calvert, N., McWilliams, R.   +13 more
core   +1 more source

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang, Zhicheng Zhou, Xue Jiang, Zhenguang Du, Yangyang Zhan, Xinli Liu   +5 more
wiley   +1 more source

Multifunctional Nanovaccine‐Radiotherapy Synergy Drives Anti‐Tumor Immunity via Multi‐Cascade Cell Death for Pancreatic Cancer Therapy

Advanced Science, EarlyView.
Machine‐learning‐driven transcriptomic analysis identifies FSTL3 as a key tumor‐microenvironment regulator in desmoplastic pancreatic adenocarcinoma. A cRGD‐modified liposome co‐loading gemcitabine and siFSTL3 serves as an irradiation‐triggered in situ nanovaccine. It synergizes with radiotherapy to induce ferroptosis and immunogenic cell death through
Chengyi Huang, Yushu Han, Xiang Liu, Chuanhao Wang, Xiaofei Zhu, Di Chen, Yangyang Gong, Liang Chen, Wenjuan Chen, Zhenyuan Miao, Bufu Tang, Huojun Zhang   +11 more
wiley   +1 more source

Impact of Histopathological Response on Outcomes After Surgical Resection Following Carbon‐Ion Radiotherapy for Pancreatic Cancer With Arterial Involvement

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim Carbon‐ion radiotherapy (CIRT) provides superior dose distribution and higher biological effectiveness than conventional X‐ray radiotherapy and has emerged as a promising component of multidisciplinary treatment for advanced pancreatic ductal adenocarcinoma (PDAC).
Kenichiro Araki, Norio Kubo, Yuhei Miyasaka, Hayato Ikota, Ryo Muranushi, Mariko Tsukagoshi, Takamichi Igarashi, Masahiko Okamoto, Tatsuya Ohno, Ken Shirabe   +9 more
wiley   +1 more source

BRD4 scilencing plus gemcitabine may be a novel therapy for triple-negative breast cancer

Zhongguo aizheng zazhi, 2016
Background and purpose: Breast cancer has the highest morbidity and mortality rate in women worldwide. Triple-negative breast cancer (TNBC) has no specific target and has low survival rate.
陈玉丽, 朱勤伟, 隋晓梅
doaj